WHO Publishes Guidance on Clinical Trial Registration and Public Disclosure of Results, Emphasizing Enhanced Transparency and Ethics

August 2, 2026

WHO Switzerland

Overview

The WHO has published guidance on clinical trial registration and public disclosure of results, referencing ClinicalTrials.gov and ICMJE policy. This guidance outlines standards for primary registries, including content, quality, accessibility, and unambiguous identification. It emphasizes the importance of registering trials at or before patient enrollment as a condition for publication in medical journals, promoting greater transparency and ethical research practices.

In Depth

Key Findings

The World Health Organization (WHO) has released comprehensive guidance on the registration of clinical trials and the public disclosure of their results. This guidance clearly outlines international standards and practices aimed at enhancing the transparency of clinical trial information and strengthening research ethics, specifically referencing ClinicalTrials.gov and the policies of the International Committee of Medical Journal Editors (ICMJE).

Technical / Clinical Details

The WHO guidance sets specific criteria that primary clinical trial registries must fulfill. These include the ‘content’ of registered information (e.g., trial objectives, interventions, primary outcomes, participant numbers), ‘quality’ of data (accuracy and completeness), ‘accessibility’ of information (easy public search and access), and ‘unambiguous identification’ of the trial (a unique ID number). A particularly crucial point highlighted is the mandatory registration of clinical trials at or before the time of first patient enrollment as a condition for publication of research findings in medical journals. This requirement is designed to minimize selective reporting and outcome bias in research, ensuring that all research findings are made public.

Background & Context

Historically, issues of ‘selective reporting’ arose where companies or research institutions would only publish favorable results or suppress negative findings. This practice hindered healthcare professionals and patients from making informed decisions about treatments and posed potential public health risks. To address this, the WHO, ICMJE, and various national regulatory bodies have strongly advocated for pre-registration of clinical trials and full disclosure of results. This initiative has significantly improved the trustworthiness of medical research and ensures that the development and evaluation of new therapies proceed through a more transparent and ethical process.

Strategic Significance & Outlook

This WHO guidance places a higher demand for transparency and accountability on the global clinical research community. Moving forward, national regulatory authorities and research ethics committees are expected to further strengthen domestic policies and procedures in alignment with these international standards. This will ensure that patient safety and public health interests are maximally protected, while simultaneously enhancing the quality and reliability of medical research. Researchers and pharmaceutical companies will increasingly need to integrate transparent information disclosure strategies from the earliest stages of development.

Source: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/guidance-registration-clinical-trials-public-disclosure-results/resources.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.